This company listing is no longer active
Resumen de acción EPE
Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Competidores de Epizyme, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.42 |
| 52 Week High | US$4.90 |
| 52 Week Low | US$0.35 |
| Beta | -0.42 |
| 1 Month Change | -2.74% |
| 3 Month Change | 178.43% |
| 1 Year Change | -69.20% |
| 3 Year Change | -88.07% |
| 5 Year Change | -88.07% |
| Change since IPO | -92.92% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| EPE | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | -3.4% | 2.1% | -1.0% |
| 1Y | -69.2% | -22.2% | 2.0% |
Rentabilidad vs. Industria: EPE underperformed the German Biotechs industry which returned -2.5% over the past year.
Rentabilidad vs. Mercado: EPE underperformed the German Market which returned -20.5% over the past year.
Volatilidad de los precios
| EPE volatility | |
|---|---|
| EPE Average Weekly Movement | 23.5% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: EPE's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: EPE's weekly volatility has increased from 17% to 23% over the past year.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2007 | 250 | Grant Bogle | www.epizyme.com |
Resumen de fundamentos de Epizyme, Inc.
| Estadísticas fundamentales de EPE | |
|---|---|
| Capitalización bursátil | €241.38m |
| Beneficios(TTM) | -€202.60m |
| Ingresos (TTM) | €51.70m |
4.7x
Ratio precio-ventas (PS)-1.2x
Ratio precio-beneficio (PE)¿Está EPE sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de EPE | |
|---|---|
| Ingresos | US$53.01m |
| Coste de los ingresos | US$20.28m |
| Beneficio bruto | US$32.73m |
| Otros gastos | US$240.47m |
| Beneficios | -US$207.73m |
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.23 |
| Margen bruto | 61.75% |
| Margen de beneficio neto | -391.88% |
| Ratio deuda/patrimonio | -1,148.4% |
¿Cómo se ha desempeñado EPE a largo plazo?
Ver rendimiento histórico y comparativa